Patents Assigned to Biochemistry
  • Patent number: 11427590
    Abstract: Small molecule inhibitors of neutral sphingomyelinase 2 (nSMase2) and their use for treating neurodegenerative diseases, such as, neurodegenerative diseases associated with high levels of ceramide, including, but not limited to Alzheimer's disease (AD), HIV-associated neurocognitive disorder (HAND), multiple sclerosis (MS), and amyotrophic lateral sclerosis (ALS), and, in other aspects, for treating cancer, are provided.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: August 30, 2022
    Assignees: The Johns Hopkins University, Institute of Organic Chemistry & Biochemistry
    Inventors: Barbara Slusher, Camilo Rojas, Ajit G. Thomas, Radim Nencka, Michal Sala, Hubert Hrebabecky, Norman Haughey
  • Patent number: 11325931
    Abstract: Methods and compounds are disclosed for treating a disease or condition by inhibiting PSMA (Prostate Specific Membrane Antigen) using prodrugs of 2-PMPA.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: May 10, 2022
    Assignees: The Johns Hopkins University, Inst of Organic Chem. and Biochemistry AS CR V.V.I
    Inventors: Barbara Slusher, Rana Rais, Marcela Krecmerova, Tomas Tichy, Pavel Majer, Andrej Jancarik
  • Patent number: 10548898
    Abstract: Described herein are compounds of Formula (I) and tautomers and pharmaceutical salts thereof, compositions and formulations containing such compounds, and methods of using and making such compounds.
    Type: Grant
    Filed: January 4, 2019
    Date of Patent: February 4, 2020
    Assignees: Gilead Sciences Inc., Institute of Organic Chemistry and Biochemistry of the AS CR, V.V.I.
    Inventors: Ondrej Baszczynski, Milan Dejmek, Yunfeng Eric Hu, Petr Jansa, Eric Lansdon, Richard L. Mackman, Petr Simon
  • Patent number: 10539551
    Abstract: A previously unrecognized fundamental property of ?1PI is to regulate the phenotypic composition of circulating and tissue-associated cells derived from hematopoietic stem cells. The present invention comprises screening for various unmodified and modified ?1PI's which are useful in the treatment of abnormalities in the number of cells of myeloid or lymphoid lineage that are associated with Human Immunodeficiency Virus-1 (HIV-1) infection, microbial infection, leukemia, solid tumor cancers, atherosclerosis, autoimmunity, stem cell transplantation, organ transplantation, and other diseases affected by cells of the immune system. The interaction of ?1PI with its receptors, cell surface Human Leucocyte Elastase (HLEcs) and Lipoprotein Receptor-related Protein (LRP), influences the level of cells of different lineages. Genetic and proteolytic modification of ?1PI is used to target these receptors to increase or decrease specific cell populations, as needed, in the various disease states.
    Type: Grant
    Filed: April 3, 2017
    Date of Patent: January 21, 2020
    Assignees: The Institute for Human Genetics and Biochemistry
    Inventor: Cynthia L. Bristow
  • Patent number: 10206926
    Abstract: Described herein are compounds of Formula (I) and tautomers and pharmaceutical salts thereof, compositions and formulations containing such compounds, and methods of using and making such compounds.
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: February 19, 2019
    Assignees: Gilead Sciences, Inc., Institute of Organic Chemistry and Biochemistry of the AS CR, V.V.I.
    Inventors: Ondrej Baszczynski, Milan Dejmek, Yunfeng Eric Hu, Petr Jansa, Eric Lansdon, Richard L. Mackman, Petr Simon
  • Publication number: 20180045644
    Abstract: The invention describes generating and use of a multi-layer plasmonic slide, wherein the plasmonic slide comprises at least 6 layers of metallic nanoparticles that can enhance the detection of fluorescent signals and wherein the plasmonic slide can be printed as a microarray of any size. The microarray containing the plasmonic slide can further be printed with a protein, a glycan, or an antibody. The multi-layer plasmonic slide is capable of detecting proteins, polynucleotides, and/or glycans at orders of magnitude lower concentration than non-plasmonic substrates.
    Type: Application
    Filed: March 7, 2016
    Publication date: February 15, 2018
    Applicants: Biochemistry
    Inventor: Jesse Baumgold
  • Patent number: 9730936
    Abstract: Described herein are compounds of Formula (I) and tautomers and pharmaceutical salts thereof, compositions and formulations containing such compounds, and methods of using and making such compounds.
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: August 15, 2017
    Assignees: Gilead Sciences, Inc., Institute of Organic Chemistry and Biochemistry of the AS CR, V.V.I.
    Inventors: Ond{hacek over (r)}ej Baszczy{hacek over (n)}ski, Milan Dejmek, Yunfeng Eric Hu, Petr Jansa, Eric Lansdon, Richard L. Mackman, Petr {hacek over (S)}imon
  • Publication number: 20170226141
    Abstract: Methods and compounds are disclosed for treating a disease or condition by inhibiting PSMA (Prostate Specific Membrane Antigen) using prodrugs of 2-PMPA.
    Type: Application
    Filed: August 6, 2015
    Publication date: August 10, 2017
    Applicants: The Johns Hopkins University, Institute of Organic Chemistry and Biochemistry as Cr v.v.i.
    Inventors: Barbara SLUSHER, Rana RAIS, Marcela KRECMEROVA, Tomas TICHY, Pavel MAJER, Andrej JANCARIK
  • Patent number: 9701677
    Abstract: Described herein are compounds of Formula (I) and tautomers and pharmaceutical salts thereof, compositions and formulations containing such compounds, and methods of using and making such compounds.
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: July 11, 2017
    Assignees: Gilead Sciences, Inc., Institute of Organic Chemistry and Biochemistry of the AS CR, V.V.I.
    Inventors: Petr Jansa, Miroslav Kvasnica, Richard L. Mackman
  • Patent number: 9624257
    Abstract: The invention provides compounds of formula I: wherein R1, R2 and R3 have values defined in the specification and a pharmaceutically acceptable salt thereof; or an optical isomer thereof; or a mixture of optical isomers, as well as compositions comprising such compounds and therapeutic methods that utilize such compounds and/or compositions.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: April 18, 2017
    Assignee: Institute of Organic Chemistry and Biochemistry of the ASCR, V.V.I.
    Inventors: Aurelie Bourderioux, Michal Hocek, Petr Naus
  • Patent number: 9612233
    Abstract: A previously unrecognized fundamental property of ?1Proteinase Inhibitor (?1PI) is to regulate the phenotypic composition of circulating and tissue-associated cells derived from hematopoietic stem cells. The present invention comprises screening for various unmodified and modified ?1PI's which are useful in the treatment of abnormalities in the number of cells of myeloid or lymphoid lineage that are associated with HIV-1 infection, microbial infection, leukemia, solid tumor cancers, atherosclerosis, autoimmunity, stem cell transplantation, organ transplantation, and other diseases affected by cells of the immune system. The interaction of ?1PI with its receptors, Human Leukocyte Elastase Cell Surface (HLECS) and Low Density Lipoprotein-Receptor Related Protein (LRP), influences the level of cells of different lineages. Genetic and proteolytic modification of ?1PI is used to target these receptors to increase or decrease specific cell populations, as needed, in the various disease states.
    Type: Grant
    Filed: November 22, 2011
    Date of Patent: April 4, 2017
    Assignees: The Institute for Human Genetics and Biochemistry
    Inventor: Cynthia L. Bristow
  • Publication number: 20160159844
    Abstract: Compounds of Formula I and a pharmaceutically acceptable salt thereof, an optical isomer thereof, or a mixture of optical isomers thereof, as well as compositions which include such compounds and therapeutic methods that utilize such compounds and/or compositions.
    Type: Application
    Filed: December 5, 2014
    Publication date: June 9, 2016
    Applicants: Institute of Organic Chemistry and Biochemistry ASCR, v.v.i., Palacky University in Olomouc
    Inventors: Michal HOCEK, Petr NAUS, Olga CALETKOVA, Marian HAJDUCH, Petr DZUBAK
  • Publication number: 20150218201
    Abstract: The invention provides compounds of formula I, wherein R1, R2 and R3 have values defined in the specification and a pharmaceutically acceptable salt thereof; or an optical isomer thereof; or a mixture of optical isomers, as well as compositions comprising such compounds and therapeutic methods that utilize such compounds and/or compositions.
    Type: Application
    Filed: April 19, 2010
    Publication date: August 6, 2015
    Applicant: Institute of Organic Chemistry and Biochemistry ASCR, V.V.I.
    Inventors: Aurelie Bourderioux, Michal Hocek, Petr Naus
  • Patent number: 8653049
    Abstract: The invention provides a compound (which can act as an adjuvant) of Formula I or Formula (II), wherein R1 R4 R5 R6 and R7 are each independently selected from hydrogen, acetyl, hydrocarbyl, a lipid moiety and a lipid acyl moiety; R2 is a hydroxyl, a hydrocarbyl, a lipid moiety, a lipid acyl moiety; or an amino hydrocarbyl group optionally substituted with a hydrocarbyl, a lipid moiety or a lipid acyl moiety; R3 and R8 are each independently selected from acetyl, a hydrocarbyl, a lipid moiety and a lipid acyl moiety; X is a peptide chain; The above normuramylglycopeptide compounds can be located in liposomes and micelles and can function as immunomodulators, along with a desired antigen (or DNA encloding the antigen), in (e.g. DNA) vaccines.
    Type: Grant
    Filed: March 17, 2009
    Date of Patent: February 18, 2014
    Assignees: Imuthes Limited, Institute of Organic Chemistry and Biochemistry AV CR, V.V.I., Vyzkumny USTAV Veterinarniho Lekarstvi, V.V.I.
    Inventors: Karsten Hipler, Andrew Miller, Jaroslav Turanek, Miroslav Ledvina
  • Patent number: 8324150
    Abstract: Use of VPg proteins, fragments or analogs thereof having the ability to bind an eukaryotic initiation factor eIF4E, for inhibiting cell-proliferation.
    Type: Grant
    Filed: June 13, 2008
    Date of Patent: December 4, 2012
    Assignees: Centre National de la Recherche Scientifique, Institute of Biochemistry and Biophysics—Polish Academy of Sciences, Universite Joseph Fourier
    Inventors: Jadwiga Chroboczek, Wlodzimierz Zagorski, Renata Grzela
  • Patent number: 8314261
    Abstract: The present invention relates to a process for the preparation of synthetic taxanes, which protects C(7)-OH with lanthanon compounds. Its advantages are simple process and firm & reliable binding. Moreover, no C(7)-acylated taxanes are produced in the subsequent steps, and hydrolysis of C(2?)-ester groups in acylated products becomes readily controllable. In the process for the preparation of synthetic taxanes, tetrahydrofuran is used in the present invention as a medium for acylation, which not only achieves the same effects as pyridine, but also avoids odor, so as to solve the problem regarding the extremely high requirements for the place of production. The present invention can be used for the preparation of not only semi-synthetic taxane using natural taxanes as raw material, but also full-synthetic taxane.
    Type: Grant
    Filed: January 17, 2005
    Date of Patent: November 20, 2012
    Assignee: Guilin Huiang Biochemistry Pharmaceutical Co. Ltd.
    Inventors: Dingning Tang, Jian Li
  • Publication number: 20120172286
    Abstract: A previously unrecognized fundamental property of ?1PI is to regulate the phenotypic composition of circulating and tissue-associated cells derived from hematopoietic stem cells. The present invention comprises screening for various unmodified and modified ?1PI's which are useful in the treatment of abnormalities in the number of cells of myeloid or lymphoid lineage that are associated with HW-1 infection, microbial infection, leukemia, solid tumor cancers, atherosclerosis, autoimmunity, stem cell transplantation, organ transplantation, and other diseases affected by cells of the immune system. The interaction of ?1PI with its receptors, HLECS and LRP, influences the level of cells of different lineages. Genetic and proteolytic modification of ?1PI is used to target these receptors to increase or decrease specific cell populations, as needed, in the various disease states.
    Type: Application
    Filed: November 22, 2011
    Publication date: July 5, 2012
    Applicant: Institute for Human Genetics and Biochemistry
    Inventor: Cynthia L. Bristow
  • Patent number: 8153787
    Abstract: The present invention provides 5-azacytosine derivatives with antiviral activity, specifically having viral replication inhibiting properties, more particularly in DNA viruses such as pox-, papilloma- and herpes viruses in humans. The invention also provides pharmaceutical compositions comprising such 5-azacytosine derivatives as active ingredients in combination with pharmaceutically acceptable carriers, which are useful for the treatment of subjects suffering from viral infections.
    Type: Grant
    Filed: December 8, 2006
    Date of Patent: April 10, 2012
    Assignees: K.U. Leuven Research & Development, Institute of Organic Chemistry and Biochemistry Academy of Sciences of the Czech Republic
    Inventors: Antonin Holy, Marcela Krecmerova, Alois Piskala, Graciela Andrei, Robert Snoeck, Erik De Clercq, Johan Neyts, Lieve Naesens
  • Patent number: 8093226
    Abstract: The invention provides compounds of formula I: wherein R1 and R2 have any of the values defined in the specification and salts thereof, as well as compositions comprising such compounds and therapeutic methods that utilize such compounds.
    Type: Grant
    Filed: January 15, 2009
    Date of Patent: January 10, 2012
    Assignee: Institute of Organic Chemistry and Biochemistry of the ASCR, V.V.I.
    Inventors: Michal Hocek, Petr Naus
  • Publication number: 20090005346
    Abstract: The present invention provides 5-azacytosine derivatives with antiviral activity, specifically having viral replication inhibiting properties, more particularly in DNA viruses such as pox-, papilloma- and herpes viruses in humans. The invention also provides pharmaceutical compositions comprising such 5-azacytosine derivatives as active ingredients in combination with pharmaceutically acceptable carriers, which are useful for the treatment of subjects suffering from viral infections.
    Type: Application
    Filed: December 8, 2006
    Publication date: January 1, 2009
    Applicants: K.U.Leuven Research & Development, Institute of Organic Chemistry and Biochemistry Academy of Sciences of the Czech Republic
    Inventors: Antonin Holy, Marcela Krecmerova, Alois Piskala, Graciela Andrei, Erik De Clercq, Robert Snoeck, Johan Neyts, Lieve Naesens